Case 1. Cartiva 1MTPJ Interposition Arthroplasty Evidence for Functional Outcome

Description

The presentation, delivered by Mark Davies, focuses on the topic of treating stage three hallux rigidus through fusion and discusses the alternative option of using a Cartiva implant. Mark starts by recognizing Anna's previous talk on the fusion procedure, deeming it the gold standard for treatment and highlighting its role as a potential solution for failed arthroplasties. He shares a clinical scenario involving a 61-year-old woman with hallux rigidus who expresses a desire to maintain joint flexibility and function, emphasizing the importance of considering the Cartiva implant due to its robust clinical evidence.



Mark outlines a significant study conducted in 2010 comparing Cartiva against traditional fusion methods across Canada and the UK, detailing the methodology and primary outcomes. He notes that the findings indicated equivalence in outcomes between Cartiva and fusion at the two-year mark. Notably, Cartiva allows for retained, and often improved, range of motion, presenting it as an advantageous alternative for patients wishing to preserve knee mobility.



He discusses long-term follow-up results, affirming Cartiva's sustainability over time, and praises the study's recognition through the Roger Mann Award for its contribution to orthopedic knowledge. Mark also recounts diverse results from different studies, particularly concerning patient demographics and satisfaction rates after installation of the Cartiva implant.



A critical point raised by Mark is the need for ease of conversion back to fusion should the Cartiva procedure fail, asserting Cartiva's flexibility without burning bridges for future treatments. In conclusion, he reiterates the appeal of Cartiva for patients like the 61-year-old female, given its high-quality design, thorough research support, and straightforward transition to fusion if desired.

DOI: 10.1302/3114-210098

Specialties